Halozyme (HALO) Stock Statistics & Valuation Metrics

Halozyme has a market cap or net worth of $7.18B. The enterprise value is $8.31B.

Halozyme has 123,221,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Halozyme’s return on equity (ROE) is 1.22 and return on invested capital (ROIC) is 22.84%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Halozyme had revenue of 1.02B and earned 444.09M in profits. Earnings per share was 3.50.

In the last 12 months, operating cash flow was 503.86M and capital expenditures -8.10M, giving a free cash flow of 495.76M billion.

Halozyme pays an annual dividend of ―, resulting in a dividend yield of ―

Halozyme upcoming earnings date is Aug 5, 2025, After Close (Confirmed).

Halozyme as a current ratio of 7.80, with Debt / Equity ratio of 312.57%

In the past 12 months, Halozyme has paid 113.04M in taxes.

Halozyme EV to EBITDA ratio is 11.35, with an EV/FCF ratio of 15.91.

Halozyme has $747.92M in cash and marketable securities with $1.51B in debt, giving a net cash position of $759.52M billion.

Gross margin is 81.81%, with operating margin of 54.32%, and net profit margin of 43.74%.

The average price target for Halozyme is $64.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy